Viewing Company Abbott Labs | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $52.5100 on 2017-09-22

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-06-15 BUY on WEAKNESS Christine Poole

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.


Price:
$48.120
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on NORTH AMERICAN ECONOMY
Owned:
Yes
2017-05-17 TOP PICK Cameron Hurst

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)


Price:
$43.080
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-05-10 COMMENT Paul Macdonald

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.


Price:
$44.500
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
No
2017-03-21 BUY David Dietze

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.


Price:
$44.800
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Unknown
2017-02-22 COMMENT Paul Macdonald

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.


Price:
$45.010
Subject:
HEALTHCARE
Bias:
BULLISH on HEALTH CARE
Owned:
Unknown
2016-09-13 WAIT Christine Poole

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.


Price:
$40.640
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2016-08-17 COMMENT Bruce Tatters

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)


Price:
$44.680
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Unknown
2016-07-28 DON'T BUY Andy Nasr

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.


Price:
$44.450
Subject:
GLOBAL
Bias:
OPTIMISTIC
Owned:
No
2016-06-22 COMMENT Paul Macdonald

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.


Price:
$38.740
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
2016-06-14 BUY Christine Poole

Acquiring St. Jude Medical to enhance their stent products, and Alere, which is a diagnostic company. The stock pulled back when they announced the St. Jude acquisition, as it is quite large. The company will probably have to issue some equity to fund both acquisitions. She really likes management. This is an attractive entry point.


Price:
$37.660
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2016-06-01 BUY Matthew McCall

Has not performed very well of late. He likes it going forward as well as their acquisition of St. Jude’s Medical, which will be accretive to the bottom line. This would be a nice time to pick up some shares.


Price:
$39.500
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Unknown
2016-05-18 COMMENT Christine Poole

Emerging markets represents about 40% of their earnings. Have a very strong branded generic division and a lot of that is in the emerging-market, so currency has been a huge head wind for them. Also, have a leading adult and infant nutritional business as well as medical devices. There was some concern that the medical device area was not growing as fast as some of their other businesses. Management is quite competent they can get things improving.


Price:
$37.750
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2016-05-11 DON'T BUY John Burke

Healthcare is a great sector, but the worst performing one year-to-date. Politicians are talking about capping prices for healthcare manufacturers, which doesn’t help. More importantly, Medicare and Medicaid US administrations are trying to cap prices and this one is being hit particularly hard. There are better names in this space.


Price:
$38.010
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
Unknown
2016-02-09 COMMENT Christine Poole

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.


Price:
$37.000
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2016-02-04 BUY on WEAKNESS Brian Acker, CA

He likes it.  Everything under healthcare has been under pressure.  Model $39 with a 3% upside.  At $31 he would be very excited.


Price:
$38.010
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US ECONOMY
Owned:
Unknown
Showing 1 to 15 of 105 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.